Iovance Biotherapeutics (IOVA) Net Cash Flow (2010 - 2026)

Iovance Biotherapeutics (IOVA) has reported Net Cash Flow for 15 consecutive years, with $33.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow fell 39.39% year-over-year to $33.6 million; the TTM figure through Mar 2026 stood at $24.0 million (down 35.06% YoY), while the FY2025 annual figure was $45.9 million, up 178.11% from the prior year.
• Net Cash Flow climbed to $33.6 million in Q1 2026 per IOVA's latest filing, from $4.4 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $311.8 million in Q1 2023 and bottomed at -$249.7 million in Q2 2023.
• Historically, Net Cash Flow has averaged $7.1 million across 5 years, with a median of $14.1 million in 2022.
• On a YoY basis, Net Cash Flow climbed as much as 2106.16% in 2023 and fell as far as 1654.74% in 2023.
• Iovance Biotherapeutics' Net Cash Flow stood at $113.4 million in 2022, then tumbled by 237.48% to -$155.9 million in 2023, then soared by 69.64% to -$47.3 million in 2024, then soared by 109.28% to $4.4 million in 2025, then surged by 666.04% to $33.6 million in 2026.
• Business Quant data shows IOVA's Net Cash Flow at $33.6 million in Q1 2026, $4.4 million in Q4 2025, and $26.3 million in Q3 2025.